Level 2, 66 Hunter Street

Sydney NSW 2000

Tel: (61-2) 9300 3344

Fax: (61-2) 9221 6333

E-mail: pnightingale@biotron.com.au

Website: www.biotron.com.au

13 January 2017

The Manager Companies

ASX Limited

20 Bridge Street

Sydney NSW 2000 (22 pages by email)

Dear Madam

BIOTRON LIMITED PRESENTS AT BIOTECH SHOWCASETM

2017

Biotron Limited advises that Dr Michelle Miller, Managing Director, will be giving the attached

presentation to the Biotech ShowcaseTM

2017 Conference being held this week in San Francisco,

California, USA.

In addition, Dr Miller will give briefings to USA institutional investors and pharmaceutical company

representatives as part of activities surrounding the annual JP Morgan Healthcare Conference. This

is one of the most important annual healthcare investor conferences, attracting thousands of

healthcare and life science business executives, as well as investors and analysts, to San Francisco.

The Biotech ShowcaseTM

features corporate presentations by innovative life science companies to an

audience of public and private investors, business development executives and professional advisors

who are interested in investment opportunities and collaborations. Now in its ninth year, it expects

to attract upwards of 2,800 attendees.

Yours sincerely

Peter J. Nightingale

Company Secretary

pjn8740 For

per

sona

l use

onl

y

BIOTRONLIMITED(ASX:BIT)Update–January2017

For

per

sona

l use

onl

y

Forward Looking Statements

Thispresenta,onmaycontainforward-lookingstatementswithrespecttothefinancialcondi,on,resultsandbusinessachievements/performanceofBiotronLimited(ACN086399144)andcertainof the plans and objec,ves of its management. These statements are statements that are nothistoricalfacts.Wordssuchas“should”,“expects”,“an,cipates”,“es,mates”,“believes”orsimilarexpressions,astheyrelatetoBiotronLimited,areintendedtoiden,fyforward-lookingstatements.By their nature, forward-looking statements involve risk and uncertainty because they reflectBiotron’scurrentexpecta,onsandassump,onsastofutureeventsandcircumstancesthatmaynotprove accurate. There is no guarantee that the expected events, trends or results will actuallyoccur. Any changes in such assump,ons or expecta,ons could cause actual results to differmateriallyfromcurrentexpecta,ons.

For

per

sona

l use

onl

y

BiotronLimited

•  SpunoutfromJohnCur,nSchoolofMedicalResearchattheAustralianNa,onalUniversityin1999

•  ListedonASXinJan2001(ASX:BIT)

•  HeadquarteredinSydney,Australia

•  Directors•  MichaelHoy Chairman

•  MichelleMillerCEO&ManagingDirector;ex-Johnson&JohnsonResearch;ex-Start-upAustraliabiotechfund

•  DenisWade Independentnon-execu,vedirector;ex-J&J(ChairmanandMDJohnson&JohnsonResearch); DirectorofHeartwareInc(NASDAQ:HTWR)

•  SusanPond Independentnon-execu,vedirector;ex-J&J(ChairmanandMDJohnson&JohnsonResearch)

•  RobThomas Independentnon-execu,vedirector;DirectorofHeartwareInc(NASDAQ:HTWR);Starpharma (ASX:SPL),REVAMedicalLimited(ASX:RVA);VirginAustraliaLimited(ASX:VAH)

Slide2

For

per

sona

l use

onl

y

Biotron–LeaderinViroporin-TargeHngDrugDevelopment

•  Biotron’scoreexper,seisbasedondesignanddevelopmentofanewclassofan,viraldrugstarge,ngviralionchannelproteins(viroporins)

•  Viroporinsarepresentinbroadrangeofviruses:

•  Influenza(M2),HIV-1(Vpu),HepC(p7),DengueandWestNile(Mprotein),SARS(Eprotein)andothers

•  Broadplakorm:

•  Rapid,proprietaryprimarybacterialcell-basedscreeningassaysfortargetproteins

•  Targetedlibraryofcompoundsthattargettheseviralproteins

•  Pipelineofinternally-generated,first-in-classsmallmoleculeviroporininhibitorsforkeymarkets

Slide3

For

per

sona

l use

onl

y

Viroporins

Slide4

•  Smallhydrophobicproteinswithionchannelac,vity

•  Formhydrophilicporesinhostcellmembranes

•  Keystagesoftheviralcyclesuchasvirusuncoa,ng,transportandmatura,onareion-influencedprocessesinmanyviralspecies

•  Crucialforviralpathogenicityduetoinvolvementinvariousstepsofviruslifecycles

•  Idealtherapeu,ctargetsNatureReviewsMicrobiology10,563-574

For

per

sona

l use

onl

y

Biotron’sCoreTechnology

Slide5

Designedlibraryofcompoundstotargetviroporins:

IniHally>250compoundsdesignedandsynthesised;librarynow~350

BIT225(HIV-1andHCV)

BIT314(HCV)

Compoundsscreenedinproprietaryassaysetupforeachvirustargete.g.HIV-1Vpu;HCVp7;InfluenzaM2;DengueM;CoronavirusE.

Hitstestedagainstvirusincellcultures

Leadop,misa,onandselec,on

OTHER“HITS”INLIBRARYinclude:-  InfluenzaAandB-  Coronaviruses

-  IncludingSARS-  Epstein-Barrvirus(EBV)-  HepaHHsBvirus(HBV)-  Zikavirus-  others

BIT225:-  RepresentaHonofthevalue

thatresideswithinBiotron’scoreexperHse;

-  Valuable,Phase2clinicalasset

DENGUE–SeveralcompoundswithpromisinganHviralacHvity

OTHERVIRUSES–Secondaryscreeningofhitsagainstkeyvirusese.g.HepB,influenza,Zika

For

per

sona

l use

onl

y

BIT225Snapshot

-  PreparedbasedonaboveaoertheAugustBoardmee,ng

-  Guidedthewordingoftheprospectusdraoandtheuseofproceeds

-  Whilecapitalrequirementsaredeterminedbasedonproposedplan,thefinalschedule

ofworkwillbelargelydictatedbyavailablecapital

-  FirstinclassdrugandnewdrugtargetfortreatmentofHIV-1andHepa,,sCvirus(HCV)

-  Sevenclinicaltrialscompleted;anotherisfullyrecruitedwithdataexpected1Q16

-  Over200subjectsdosedintrialstodate

-  PromisingclinicalefficacyagainstHIV-1andHCV

-  HCVGT1(BIT225-005)–100%receiving400mgBIDfor28daysincombina,onwith48weeksIFN/RBV(perprotocol)werevirus-freeat48weeks

-  HIV-1/HCVGT3(BIT225-006)–100%receiving300mgBIDfor28daysincombina,onwith48weeksIFN/RBV(perprotocol)achievedSVR12i.e.curedofHCVinfec,on

-  BIT225increasestherateatwhichHCViscleared

-  BIT225efficientlyinhibitsHIV-1replica,oninmacrophagereservoircellsinvitroandinvivo(BIT225-004)

Slide7

For

per

sona

l use

onl

y

BIT225–FirstofaNewClassofHCVDAADrugs

ü  Novel,oral,smallmoleculecompound

ü  Onlyoneofitsclass(p7inhibitor)inclinicaltrials

ü  Inhibitsviralassemblyandinfec,vity

ü  Pan-genotypeac,vity:

ü  Ac,veinvitroagainstallmaingenotypes

ü  Clinicallyac,veagainsthard-to-treatHCVGT1(1aand1b)andGT3

ü  Seekingpartnershipsforfurtherdevelopment,inpar,cularinAsia

POLYMERASE/PROTEASEINHIBITORSe.g.Sofosbuvir/Simeprevir

BIT225-ASSEMBLY/BUDDINGINHIBITOR

Slide8

For

per

sona

l use

onl

y

HIV-1:TowardsaCure

•  Over1.1millionpeoplelivingwithHIV-1intheUSA,with1in6unawareofdiagnosis

•  US$11.9bnsalesinUS,EuropeandJapanin2013;expectedtogrowtoUS$16.8bnby2020

•  HIV-1pa,entsneedtostayonan,retroviraldrugs(ART)tokeepviruslevelsundercontrol

•  Long-termhealthimplica,onseveninpa,entsonan,retroviraldrugse.g.HAND,immuneac,va,on,etc

•  Newmodeofac,onsdrugsareneededtoeradicateorcureHIV-1infec,on

Slide9

For

per

sona

l use

onl

y

HIV-1Reservoirs

•  HIV-1remainshiddeninreservoirs,leadingtochronic,life-longinfec,on

–  Invisibletobody’simmunedefenses

–  Notsensi,vetoan,-HIV-1drugs

•  Eradica,onwillrequiremul,pleapproaches;approachesinclude:

–  An,-latencyagentsforlatently-infectedTcells

–  Drugstomodifyimmuneresponse

–  Drugstarge,ngHIV-1inmacrophagelineagecells

Slide10

MarioStevensonScien@ficAmerican299,78-83(2008)

For

per

sona

l use

onl

y

•  BIT225inhibitsassemblyandbuddingofnewvirusinmacrophages•  Phase2atrial(004)demonstratedthatBIT225canreduceHIV-1levelsinmacrophagecellsinvivo,

parallelinginvitrostudies(Wilkinsonetal,JAn,microbChemother.2015Nov29.pii:dkv389.[Epubaheadofprint])

•  Poten,albenefitsonimmuneagingandHIV-associateddemen,a•  Poten,alforuseinfutureviruseradica,ontreatment

BIT225TargetsHIV-1inReservoirCells

Slide11

Time(days)+HIV-1

50100150200

16 17 19 21 22 23 24 25 26 27 28

+BIT225

BIT225StopsHIV-1Replica7onA B

(A)UntreatedControls (B)BIT225treatedcells

For

per

sona

l use

onl

y

BIT225–ProvenClinicalAcHvityAgainstHIV-1

•  BIT225-004:Phase1b/2arandomised,placebocontrolled,double-blindtrial

–  21pa,ents,HIV-1posi,ve,treatment-naïve;10daysdosingwithBIT225(monotherapy)

•  Resultsdemonstratedthat:

1.   BIT225significantlyreducesHIV-1levelsinthemacrophage(reservoir)cellsBIT225cancrosstheblood-brainbarrier,openingupthepossibilityoftreatmentofAIDS-relateddemenHa

2.   BIT225reducedmyeloid-specificimmuneacHvaHonmarkersduringtrial

2 4 6 8

10 12 14 16

5 10 15 20 25

HIV-1Re

plica,

on(p

g/20

0uL)

TimeinCo-culture(days)

BIT225Placebo

ResultssupportapotenHalroleforBIT225incure/eradicaHonstrategies

Slide12

Phase2HIV-1trialofBIT225incombinaHonwithcurrentanH-HIV-1drugsscheduledtocommenceearly2017

For

per

sona

l use

onl

y

HIV-1ViralDynamics

BIT225-009 Hu-MouseATI

Slide13

For

per

sona

l use

onl

y

CurrentHIV-1ProgramTrials

Slide14

•  Phase2trialan,cipatedtocommenceearly2017

•  12weeksBIT225incombina,onwithcART

•  Expectedoutcome(s)–Impactonkine7csofviralloaddecayincombina7onwithARTindica7ngimpactonunderlyingviralreservoir,alsoimpactonimmuneac7va7on

•  Headlinedata3Q17

•  HumanisedMouseStudy

•  Modellingtreatmentinterrup,on(ATI)

•  Inprogress

•  Expectedoutcome(s)–impactonviralkine7csincombina7onwithART,pluspoten7alimpactonreboundonceARTisstopped

•  Data1Q17

For

per

sona

l use

onl

y

UnlockingValueinCompoundLibrary

Slide15

•  Renewedindustryinterestintarge,ngviraldiseasesincluding

•  Respiratorysyncy,alvirus(RSV)

•  Hepa,,sBvirus

•  TropicaldiseasesincludingDengue

•  Influenza(inpar,culardrugresistantstrains)

•  EbolaandMERS-CoVoutbreakshavecausedpublichealthissuesworldwide

•  BIT225hasdemonstratedtherobustnessofBiotron’sapproachwithtargeHngviroporinproteins

•  Compoundswithac,vityagainstotherkeyviruseshavebeeniden,fied;secondaryscreeningisinprogress,withtheaimofiden,fyingpoten,alcandidatestoprogressintoIND-enablingstudies

•  MainfocusremainsoncommercialisingtheCompany’sHIV-1andHCVprograms,butessen,althatotheropportuni,esaredeveloped

For

per

sona

l use

onl

y

X-axis: compound ID Y-axis: virus Z-axis: strength of hit

Compound Library is Rich Source of Hits

Slide16

For

per

sona

l use

onl

y

DengueVirusProgram

•  2.5billionpeople(40%worldpopula,on)liveinareasatriskofDengue

•  ~100millionpeopleinfectedyearly

•  Aleadingcauseofillnessanddeathintropicsandsubtropics

•  Transmissionisbymosquito;mostpreven,onprogramstargetthevector

•  NoapprovedDengue-specifictherapeu,cdrug

•  Vaccinetrialshavehaddisappoin,ngresults

•  Biotronistarge,ngDengueMprotein–SimilartargettoHIV-1/VpuandHCV/p7

•  Severalcompoundswithpromisingac,vityhavebeengenerated;testsareon-going

•  Poten,alforpan-Flavitherapeu,c

Slide17

www.sciencenews.orgFor

per

sona

l use

onl

y

HepaHHsBVirus

•  LimitedscreeningofBiotroncompoundlibraryhasgeneratedinteres,ngdata

•  Hitsiden,fied

•  Veryexperiencedscien,ficadvisoryandopera,onalteaminplaceforHBV

•  Seekingcollabora,ontoexplorehitsanddevelopprogram

Slide18

For

per

sona

l use

onl

y

SummaryI•  Uniquecoreexper,seagainstnovelviraltargets

•  Demonstratedproofofconceptofsuccessfultarge,ngofviroporinswithBIT225

•  BIT225isanovelapproachwithdemonstratedpromisingefficacyinPhase2a/2clinicaltrials

•  HCVandHIV-1arehighgrowth,mul,-billiondollarmarkets

•  Treatmentgapsremain

•  Representsanewclassofdirect-ac,ngHCVdrugs

•  Poten,altofillsignificantHCVtreatmentgaps,shortentreatmentandreducecosts

•  Poten,altoeradicateimportantHIV-1reservoirs,plusmayimpactonimmuneac,va,on

•  Robustdatapackagehasbeengeneratedtosupportcombina,onstudieswithpoten,alpartners

Slide19

For

per

sona

l use

onl

y

SummaryII

•  Technologycoreisanan,viralplakormwithnewclassofsmallmoleculeswithbroadrangeofac,vi,es

•  Extendingearlierstageprogramsforotherkeyviruses:

•  DevelopingleadsforprogramsincludingDengueandHBV

•  Iden,fyinghitsforothervirusesincludingRSV,Zika,BK,andothers

•  Denguevirus–applyingfornon-equityfundingfromUSorganisa,ons

•  Poten,altoexpandtoareasofpoten,alpartnerinterest

•  Seekingcollabora,onsforindividualprogramsoren,replakorm

Slide20

For

per

sona

l use

onl

y

DrMichelleMillerManagingDirector+61412313329mmiller@biotron.com.auwww.biotron.com.au

For

per

sona

l use

onl

y